Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.56 |
| ▸ | NPY1R | P25929 | 10/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.56 |
| ▸ | NPY2R | P49146 | 6/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31344438 | 0.99 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL31752429 | 0.98 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL31567752 | 0.96 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL29531603 | 0.96 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL31031597 | 0.95 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL31157729 | 0.95 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL31097757 | 0.94 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL31097711 | 0.94 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL30527921 | 0.94 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL30527840 | 0.94 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746919-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY OF CYTOKINES TO IMMUNE CELLS | BioNTech SE (DE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026102183-A1 | EFFECTOR CELLS HAVING ENHANCED TARGET CELL RECOGNITION | FATE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12624077-B2 | CXCR3 ligand | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-12 | — | — | US | disclosed |
| US-12624122-B2 | Affinity maturated TAG72 specific single chain antibodies | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| CN-115947868-B | CXCL-BPI fusion protein and use thereof | 安君(北京)基因科技有限责任公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125434-A1 | CXCL-BPI FUSION PROTEIN AND USE THEREOF | BEIJING ANJUN GENETECH CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| US-12617849-B2 | Antigen specific CD19-targeted CAR-T cells | Atara Biotherapeutics, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12605372-B2 | Combination therapy for the treatment of cancer | CELGENE CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-12599621-B2 | Enhancing anti-tumor response in melanoma cells with defective sting signaling | H. LEE MOFFITT CANCER CENTER (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4720105-A1 | CD40L MONOMERS AND METHODS OF THEIR USE IN TIL ENHANCEMENT VIA EX VIVO STIMULATION | H. Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-11319379-B2 | Affinity maturated TAG72 specific single chain antibodies | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3981428-A1 | PROTEASE SUBSTRATE, AND POLYPEPTIDE INCLUDING PROTEASE CLEAVAGE SEQUENCE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-04-13 | — | — | EP | disclosed |
| US-11286306-B2 | TLR9-binding chimeric antigen receptors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220088073-A1 | CHIMERIC ANTIGEN RECEPTORS WITH ENHANCED TUMOR INFILTRATION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-03-24 | — | — | US | disclosed |
| CN-107253992-B | Monoclonal antibody against HER2 | 根马布股份公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3962955-A1 | ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS | Atara Biotherapeutics, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114127277-A | Protease substrates and polypeptides comprising protease cleavage sequences | 中外制药株式会社 | 2022-03-01 | — | — | CN | disclosed |
| CN-114026128-A | CAR-T cells antigen-specifically targeted to CD19 | 阿塔拉生物制药股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-107660214-B | Bispecific antibodies against CD3 and CD20 | 根马布股份公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11230604-B2 | Antibodies against human CD38 | GENMAB A/S (DK) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624077-B2 | CXCR3 ligand | CXCL10, CXCR3, CCL5 | NPY4R 557/4885NPY1R 944/4885NPY5R 2639/4885 |
| US-11230604-B2 | Antibodies against human CD38 | CD38, CD22, CD2 | NPY4R 4600/4885NPY1R 4246/4885NPY5R 4221/4885 |
| US-12605372-B2 | Combination therapy for the treatment of cancer | IGLV6-57, BCL6, CTNND1 | NPY4R 1540/4885NPY1R 2279/4885NPY5R 1844/4885 |
| US-12624122-B2 | Affinity maturated TAG72 specific single chain antibodies | IGLV6-57, CD74, IGSF11 | NPY4R 2899/4885NPY1R 2136/4885NPY5R 3172/4885 |
| US-12617849-B2 | Antigen specific CD19-targeted CAR-T cells | BCL9, BCL9L, BCR | NPY4R 2701/4885NPY1R 1868/4885NPY5R 2679/4885 |
| US-12599621-B2 | Enhancing anti-tumor response in melanoma cells with defective sting signaling | STING1, CGAS, MAVS | NPY4R 3313/4885NPY1R 2053/4885NPY5R 2777/4885 |
| US-20260125434-A1 | CXCL-BPI FUSION PROTEIN AND USE THEREOF | CXCL8, CXCL10, CCL5 | NPY4R 1510/4885NPY1R 1756/4885NPY5R 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.